Publications

Export 15695 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D [E] F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
E
Eswi, A., R. M. N. Aboushady, and A. A. A. E. Hamid, "Knowledge of Pregnant Women Regarding Folic Acid: A Suggested Plan of Action", International Journal of Health Sciences & Research, vol. 4, issue 9, pp. 195-205, 2014. first_paper_folic_acid.pdf
Eswi, A. 1, and A. 2 Khalil, "Prenatal Attachment and Fetal Health Locus of Control among Low Risk and High Risk Pregnant Women", World Applied Sciences Journal , issue 18 (4):, pp. 462-471, 2012. 1_1.pdf
Eswi, A., M. N. Badr, H. G. Eskander, and S. Elmghwry, "Families who have experienced the loss of someone in 25th January revolution: A phenomenological study", 4th international scientific nursing conference 2015- faculty of nursing Cairo university , Egypt, December 2015. abstract__phenomenological_study.pdf
et.al., A. E. H., "AMLTA (2018): International Conference on Advanced Machine Learning Technologies and Applications", AMLTA (2018): International Conference on Advanced Machine Learning Technologies and Applications, Cairo, Springer, 2018.
Etemadnia, E., K. Abdelghany, and A. E. Hassan, "A Network Partitioning Methodology for Distributed Traffic Management Applications", Transportmetrica A: Transport Science, vol. 10, issue 6, pp. 518-532, 2013.
Etemadnia, H., A. H. M. E. D. HASSAN, S. Goetz, and K. Abdelghany, "Wholesale Hub Locations in Food Supply Chains", Transportation Research Record, vol. 2379, no. 1, pp. 80-89, 2013. AbstractWebsite

This paper addresses the wholesale hub location problem in food supply chains. The paper aims to design an optimal hub location network to serve food consumption markets through efficient connections with production sites. These optimal locations can be compared with the current locations of hubs to determine whether changes could lead to greater efficiencies. The model is mathematically formulated as a mixed-integer programming problem. The model minimizes the total network costs, which include the transportation of goods and the construction of hubs. The mathematical program considers several constraints on travel distance, hub capital cost and capacity, road condition, and transportation cost. Several experiments are conducted to test the sensitivity of the model to changes in parameters such as the food's average travel distance, the maximum hub capacity, and the transportation cost. Then, a real-world application is made to the Northeast United States livestock industry. Finally, the results show the effect of the changes in model parameters on the optimal hub network design (i.e., the number of hubs and the selection of hub locations).

Etman, R. H., S. A. Barsoum, I. G. A. Ibrahim, W. R. El-Ashmawy, and K. A. Abou-Gazia, "Evaluation of efficacy of some serological tests used for diagnosis of brucellosis in cattle in Egypt using latent class analysis", Sokoto Journal of Veterinary Sciences, vol. Volume 12 , issue (Number1), pp. 1-7, 2014. Abstract79-1375702614.pdfWebsite

In this study serum samples were collected from 4 different groups of cattle, Group I (non-vaccinated Brucella infected group), Group II (Vaccinated Brucella infected group), Group III (Non-vaccinated Brucella free group) and Group IV (vaccinated Brucella free group). These samples were subjected to the different serological tests including Rose Bengal plate antigen test, Tube Agglutination test, Rivanol test, Indirect Enzyme Linked Immunosorbent Assay and Competitive Enzyme Linked Immunosorbent Assay. Statistical analysis of the obtained results in different cattle groups was carried out using Latent Class Analysis (Lem model). The prevalence of brucellosis was 6.4%, the sensitivity of RBPT was 96.1% while its specificity was 99.3%, the sensitivity of Rivanol test was 85% while its specificity was 100%, the sensitivity of Indirect Enzyme Linked Immunosorbent assay was 100% while its specificity was 98.3 % and the sensitivity of Competitive Enzyme Linked Immunosorbent assay was 97.1% while its specificity was 100%. The results proved that, the most sensitive test was Indirect Enzyme Linked Immunosorbent assay while the most specific test was Competitive Enzyme Linked Immunosorbent assay. This study therefore, recommends the use of Indirect Enzyme Linked Immunosorbent assay as a screening test and Competitive Enzyme Linked Immunosorbent assay as a confirmatory test. Bacteriological examination was carried out on supramammary lymph nodes and spleen of some slaughtered seropositive cattle, the rate of isolation was 25% from non-vaccinated infected group and 10% from vaccinated infected group. Brucella melitensis biovar3 was recovered only from supramammary lymph nodes.

Etman, A. M., "Homer in The Arab World", Receptions of Antiquity, 2011.
Etreby, R. E., W. elakel, M. Said, M. El Kassas, S. Seif, T. Elbaz, M. E. Raziky, S. Abdel Rehim, S. Zaky, R. Fouad, et al., "Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.", Liver international : official journal of the International Association for the Study of the Liver, vol. 37, issue 4, pp. 534-541, 2017 Apr. Abstract

BACKGROUND & AIMS: Major changes have emerged during the last few years in the therapy of chronic HCV. Several direct acting antiviral agents have been developed showing potent activity with higher rates of sustained virological response, even in difficult-to-treat patients. This study explores real life experience concerning efficacy, safety and possible predictors of response for the first cohort of Egyptian patients with chronic HCV genotype IV treated with Sofosbuvir/Simprevir combination therapy.

METHODS: This real life study recruited the first (6211) chronic HCV genotype IV Egyptian patients, who received antiviral therapy in viral hepatitis specialized treatment centres affiliated to the National committee for control of viral hepatitis. All enrolled patients received 12 weeks course of daily combination of sofosbuvir (400 mg) and simeprevir (150 mg). Patients were closely monitored for treatment safety and efficacy.

RESULTS: Overall sustained virological response 12 rate was 94.0% while the end of treatment response rate was 97.6%. sustained virological response 12 rates in easy and difficult-to-treat groups were 96% and 93% respectively. Univariate and multivariate logistic regression analysis revealed significant association of low albumin (<3.5), cirrhosis and Fib-4 score (>3.25) with treatment failure. Fatal adverse events occurred in 23/6211 cases (0.37%) due to liver cell failure adverse events or SAEs leading to treatment discontinuation occurred in 97 patients (1.6%).

CONCLUSION: Sofosbuvir/Simeprevir combination is an effective and well tolerated regimen for patients with chronic HCV genotype IV.

Etreby, R. E., M. A. Elraouf, A. Fouad, M. Nasser, M. A. Bassiouni, N. Zayed, A. Yosry, and Z. abdellatif, "Screening for chronic hepatitis C and chronic hepatitis B infections among pregnant females: a cross-sectional study", Egyptian Liver Journal, vol. 11, issue 43, pp. 1-5, 2021.
Etreby, R. E., W. elakel, T. Elbaz, M. El Raziky, and G. Esmat, "Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients", Liver International, vol. 37, issue 4, pp. 534-541, 2017.
Etreby, R. E., W. elakel, M. Said, M. El Kassas, S. Seif, T. Elbaz, M. E. Raziky, S. Abdel Rehim, S. Zaky, R. Fouad, et al., "Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.", Liver international : official journal of the International Association for the Study of the Liver, vol. 37, issue 4, pp. 534-541, 2017 04. Abstract

BACKGROUND & AIMS: Major changes have emerged during the last few years in the therapy of chronic HCV. Several direct acting antiviral agents have been developed showing potent activity with higher rates of sustained virological response, even in difficult-to-treat patients. This study explores real life experience concerning efficacy, safety and possible predictors of response for the first cohort of Egyptian patients with chronic HCV genotype IV treated with Sofosbuvir/Simprevir combination therapy.

METHODS: This real life study recruited the first (6211) chronic HCV genotype IV Egyptian patients, who received antiviral therapy in viral hepatitis specialized treatment centres affiliated to the National committee for control of viral hepatitis. All enrolled patients received 12 weeks course of daily combination of sofosbuvir (400 mg) and simeprevir (150 mg). Patients were closely monitored for treatment safety and efficacy.

RESULTS: Overall sustained virological response 12 rate was 94.0% while the end of treatment response rate was 97.6%. sustained virological response 12 rates in easy and difficult-to-treat groups were 96% and 93% respectively. Univariate and multivariate logistic regression analysis revealed significant association of low albumin (<3.5), cirrhosis and Fib-4 score (>3.25) with treatment failure. Fatal adverse events occurred in 23/6211 cases (0.37%) due to liver cell failure adverse events or SAEs leading to treatment discontinuation occurred in 97 patients (1.6%).

CONCLUSION: Sofosbuvir/Simeprevir combination is an effective and well tolerated regimen for patients with chronic HCV genotype IV.

Etreby, R. E., W. elakel, M. E. Raziky, and G. Esmat, "Response to Real life Egyptian experience of efficacy / safety of Simeprevir\ Sofosbuvir in HCV genotype IV.", Liver international : official journal of the International Association for the Study of the Liver, vol. 37, issue 5, pp. 766, 2017 May. ilc2017-rs-3693_response_to_letter_to_editor.pdf
Etreby, R. E., M. Said, Z. abdellatif, Y. Saad, M. E. Serafy, H. Dabes, K. Elsaeed, Y. El-Shazly, and W. Doss, "High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy.", Hepatology international, vol. 12, issue 2, pp. 143-148, 2018. Abstract

BACKGROUND: HCV is associated with several extra hepatic diseases including thyroid dysfunction. This study aims at evaluating prevalence of thyroid dysfunction and its possible predictors in a large cohort of HCV GT4-infected patients, and the role of thyroid dysfunction as a predictor of response in the setting of direct acting antivirals (DAAs).

METHODS: Patients registered on the web-based registry system to receive therapy for chronic HCV in Beheira governorate viral hepatitis specialized treatment center affiliated to the National committee for control of viral hepatitis (NCCVH), Ministry of health, Egypt in the period from January 2015 to October 2016. Their data were exported and analyzed for the prevalence of thyroid dysfunction and its associated variables.

RESULTS: Out of 13,402 patients, 2833 (21.1%) had elevated TSH level > 4.5 mIU/l (hypothyroidism). Female gender (62.7%), older age, higher FIB4, AST, and BMI and lower albumin were significantly associated with elevated TSH level on univariate analysis, while liver stiffness measured by fibroscan was not significantly associated. On the other hand, 466 patients (3.5%) showed low TSH level < 0.4 mIU/l (hyperthyroidism). Older age (median 52 years) and male gender (51.5%) were the only significantly associated variables. No association was found between SVR and baseline TSH level. Follow-up of 236 patients after SVR revealed improvement in TSH level in 80% of them.

CONCLUSION: Hypothyroidism is prevalent in patients with chronic HCV GT4, and is influenced by patient gender and age. Pretreatment TSH does not affect SVR after DAAs. Despite limited data SVR achievement after DAAs improves thyroid dysfunction.

Etreby, R. E., M. S. Abdel-Aziz, G. Esmat, and M. E. Raziky, "Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients", Liver International, pp. 1-8, 2016. liv13266.pdf
Etreby, R. E., W. elakel, M. E. Raziky, and G. Esmat, "Response to Real life Egyptian experience of efficacy / safety of Simeprevir\ Sofosbuvir in HCV genotype IV.", Liver international : official journal of the International Association for the Study of the Liver, vol. 37, issue 5, pp. 766, 2017 May.
Etreby, R. E., M. Said, Z. abdellatif, Y. Saad, M. E. Serafy, H. Dabes, K. Elsaeed, Y. El-Shazly, and W. Doss, "High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy.", Hepatology international, vol. 12, issue 2, pp. 143-148, 2018 Mar. Abstract

BACKGROUND: HCV is associated with several extra hepatic diseases including thyroid dysfunction. This study aims at evaluating prevalence of thyroid dysfunction and its possible predictors in a large cohort of HCV GT4-infected patients, and the role of thyroid dysfunction as a predictor of response in the setting of direct acting antivirals (DAAs).

METHODS: Patients registered on the web-based registry system to receive therapy for chronic HCV in Beheira governorate viral hepatitis specialized treatment center affiliated to the National committee for control of viral hepatitis (NCCVH), Ministry of health, Egypt in the period from January 2015 to October 2016. Their data were exported and analyzed for the prevalence of thyroid dysfunction and its associated variables.

RESULTS: Out of 13,402 patients, 2833 (21.1%) had elevated TSH level > 4.5 mIU/l (hypothyroidism). Female gender (62.7%), older age, higher FIB4, AST, and BMI and lower albumin were significantly associated with elevated TSH level on univariate analysis, while liver stiffness measured by fibroscan was not significantly associated. On the other hand, 466 patients (3.5%) showed low TSH level < 0.4 mIU/l (hyperthyroidism). Older age (median 52 years) and male gender (51.5%) were the only significantly associated variables. No association was found between SVR and baseline TSH level. Follow-up of 236 patients after SVR revealed improvement in TSH level in 80% of them.

CONCLUSION: Hypothyroidism is prevalent in patients with chronic HCV GT4, and is influenced by patient gender and age. Pretreatment TSH does not affect SVR after DAAs. Despite limited data SVR achievement after DAAs improves thyroid dysfunction.

Etreby, R. E., M. Said, Z. abdellatif, Y. Saad, M. E. Serafy, H. Dabes, K. Elsaeed, Y. El-Shazly, and W. Doss, "High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy.", Hepatology international, vol. 12, issue 2, pp. 143-148, 2018. Abstract

BACKGROUND: HCV is associated with several extra hepatic diseases including thyroid dysfunction. This study aims at evaluating prevalence of thyroid dysfunction and its possible predictors in a large cohort of HCV GT4-infected patients, and the role of thyroid dysfunction as a predictor of response in the setting of direct acting antivirals (DAAs).

METHODS: Patients registered on the web-based registry system to receive therapy for chronic HCV in Beheira governorate viral hepatitis specialized treatment center affiliated to the National committee for control of viral hepatitis (NCCVH), Ministry of health, Egypt in the period from January 2015 to October 2016. Their data were exported and analyzed for the prevalence of thyroid dysfunction and its associated variables.

RESULTS: Out of 13,402 patients, 2833 (21.1%) had elevated TSH level > 4.5 mIU/l (hypothyroidism). Female gender (62.7%), older age, higher FIB4, AST, and BMI and lower albumin were significantly associated with elevated TSH level on univariate analysis, while liver stiffness measured by fibroscan was not significantly associated. On the other hand, 466 patients (3.5%) showed low TSH level < 0.4 mIU/l (hyperthyroidism). Older age (median 52 years) and male gender (51.5%) were the only significantly associated variables. No association was found between SVR and baseline TSH level. Follow-up of 236 patients after SVR revealed improvement in TSH level in 80% of them.

CONCLUSION: Hypothyroidism is prevalent in patients with chronic HCV GT4, and is influenced by patient gender and age. Pretreatment TSH does not affect SVR after DAAs. Despite limited data SVR achievement after DAAs improves thyroid dysfunction.

Etreby, R. E., M. Said, Z. abdellatif, Y. Saad, M. E. Serafy, H. Dabes, K. Elsaeed, Y. El-Shazly, and W. Doss, "High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy.", Hepatology international, vol. 12, issue 2, pp. 143-148, 2018. Abstract

BACKGROUND: HCV is associated with several extra hepatic diseases including thyroid dysfunction. This study aims at evaluating prevalence of thyroid dysfunction and its possible predictors in a large cohort of HCV GT4-infected patients, and the role of thyroid dysfunction as a predictor of response in the setting of direct acting antivirals (DAAs).

METHODS: Patients registered on the web-based registry system to receive therapy for chronic HCV in Beheira governorate viral hepatitis specialized treatment center affiliated to the National committee for control of viral hepatitis (NCCVH), Ministry of health, Egypt in the period from January 2015 to October 2016. Their data were exported and analyzed for the prevalence of thyroid dysfunction and its associated variables.

RESULTS: Out of 13,402 patients, 2833 (21.1%) had elevated TSH level > 4.5 mIU/l (hypothyroidism). Female gender (62.7%), older age, higher FIB4, AST, and BMI and lower albumin were significantly associated with elevated TSH level on univariate analysis, while liver stiffness measured by fibroscan was not significantly associated. On the other hand, 466 patients (3.5%) showed low TSH level < 0.4 mIU/l (hyperthyroidism). Older age (median 52 years) and male gender (51.5%) were the only significantly associated variables. No association was found between SVR and baseline TSH level. Follow-up of 236 patients after SVR revealed improvement in TSH level in 80% of them.

CONCLUSION: Hypothyroidism is prevalent in patients with chronic HCV GT4, and is influenced by patient gender and age. Pretreatment TSH does not affect SVR after DAAs. Despite limited data SVR achievement after DAAs improves thyroid dysfunction.

Etreby, R. E., W. elakel, M. Said, M. El Kassas, S. Seif, T. Elbaz, M. E. Raziky, S. Abdel Rehim, S. Zaky, R. Fouad, et al., "Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.", Liver international : official journal of the International Association for the Study of the Liver, vol. 37, issue 4, pp. 534-541, 2017. Abstract

BACKGROUND & AIMS: Major changes have emerged during the last few years in the therapy of chronic HCV. Several direct acting antiviral agents have been developed showing potent activity with higher rates of sustained virological response, even in difficult-to-treat patients. This study explores real life experience concerning efficacy, safety and possible predictors of response for the first cohort of Egyptian patients with chronic HCV genotype IV treated with Sofosbuvir/Simprevir combination therapy.

METHODS: This real life study recruited the first (6211) chronic HCV genotype IV Egyptian patients, who received antiviral therapy in viral hepatitis specialized treatment centres affiliated to the National committee for control of viral hepatitis. All enrolled patients received 12 weeks course of daily combination of sofosbuvir (400 mg) and simeprevir (150 mg). Patients were closely monitored for treatment safety and efficacy.

RESULTS: Overall sustained virological response 12 rate was 94.0% while the end of treatment response rate was 97.6%. sustained virological response 12 rates in easy and difficult-to-treat groups were 96% and 93% respectively. Univariate and multivariate logistic regression analysis revealed significant association of low albumin (<3.5), cirrhosis and Fib-4 score (>3.25) with treatment failure. Fatal adverse events occurred in 23/6211 cases (0.37%) due to liver cell failure adverse events or SAEs leading to treatment discontinuation occurred in 97 patients (1.6%).

CONCLUSION: Sofosbuvir/Simeprevir combination is an effective and well tolerated regimen for patients with chronic HCV genotype IV.

Etreby, R. E., M. Anees, M. Naguib, A. Kobtan, A. Helmy, N. Khalaf, S. Mansour, M. Hassany, W. elakel, A. Hashem, et al., "The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents.", Expert review of gastroenterology & hepatology, vol. 15, issue 1, pp. 103-110, 2021. Abstract

OBJECTIVES: This study aims to assess the changes of lipid profile in chronic HCV patients; before, during, and after treatment with DAAs and their association with treatment response.

METHODS: 301 chronic HCV patients who received SOF-based therapy were included. Serum lipid profile was assessed at different check points; baseline, 6 weeks on treatment, end of treatment (EOT) and 12 weeks after EOT; and compared between SVR and non-SVR groups.

RESULTS: SVR group had significantly higher baseline lipid parameters compared to non-SVR group with significant increase in lipid parameters at different time points apart from HDL-C. Non-SVR group showed non-significant change in lipid parameters apart from LDL-C. On week6 on treatment, cholesterol level > 125 mg/dl was 92.8% sensitive, 97.3% specific with 95.5% NPV, and AUC of 0.989 in prediction of SVR. Similarly, LDL > 57 mg/dl was 83.7% sensitive, 100% specific with 93.3%, NPV and AUC of 0.952. Baseline cholesterol and LDL were significantly associated with SVR.

CONCLUSION: Higher baseline lipid parameters and their further elevation starting from week 6 on treatment are good predictors of SVR in HCV patients. Successful HCV therapy with DAAs is associated with a significant increase in lipid parameters.

Etsassala, N. G. E. R., A. O. Adeloye, A. E. - Halawany, A. A. Hussein, and E. I. Iwuoha, "Investigation of In-Vitro Antioxidant and Electrochemical Activities of Isolated Compounds from Salvia chamelaeagnea PJ Bergius Extract", Antioxidants, vol. 8, issue 4: Multidisciplinary Digital Publishing Institute, pp. 98, 2019. Abstract
n/a
Ettouney, S. M., and F. R. Fricke, "Courtyard acoustics", Applied Acoustics, vol. 6, no. 2: Elsevier, pp. 119–132, 1973. Abstract
n/a
Ettouney, R. S., and M. A. El-Rifai, "Sensitivity of orifice meter gas flow computations", Journal of Petroleum Science and Engineering, vol. 80, issue 1, pp. 102–106, 2011. CU-PDF